Singapore Clinical Trial: Healthy longevity with rapamycin (LONGER)

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Healthy longevity with rapamycin (LONGER)'. The following are the other relevant details related ... Read More

Singapore Clinical Trial: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcom... Read More

Singapore Clinical Trial: Efficacy and safety of LUCONAC ® External Solution for the treatment of Onychomycosis in anopen label head-to-head comparison with Amorolfine Nail Lacquer.

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Efficacy and safety of LUCONAC ® External Solution for the treatment of Onychomycosis in anopen l... Read More

Singapore Clinical Trial: A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a ... Read More

Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, ... Read More

Singapore Clinical Trial: Using AS01 adjuvant to improve immune response in older adults through trained immunity

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Using AS01 adjuvant to improve immune response in older adults through trained immunity'. The fol... Read More

Singapore Clinical Trial: A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccination and its impact on subsequent vaccination response

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccinati... Read More

Singapore Clinical Trial: A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability... Read More

Singapore Clinical Trial: A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate(ADC), in Participants with Advanced HER2+ Solid Tumors

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Pr... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzuma... Read More

• ««
• «
• 1589
• 1590
• 1591
• 1592
• 1593
• 1594
• 1595
• 1596
• 1597
• 1598
• »
• »»